Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edgewise Therapeutics (EWTX) Operating Leases (2022 - 2026)

Edgewise Therapeutics has reported Operating Leases over the past 5 years, most recently at $2.8 million for Q1 2026.

  • Quarterly results put Operating Leases at $2.8 million for Q1 2026, down 21.96% from a year ago — trailing twelve months through Mar 2026 was $2.8 million (down 21.96% YoY), and the annual figure for FY2025 was $3.0 million, down 20.45%.
  • Operating Leases reached $2.8 million in Q1 2026 per EWTX's latest filing, down from $3.0 million in the prior quarter.
  • Across five years, Operating Leases topped out at $4.8 million in Q1 2023 and bottomed at $1.6 million in Q2 2022.
  • Median Operating Leases over the past 5 years was $3.6 million (2025), compared with a mean of $3.5 million.
  • The largest annual shift saw Operating Leases skyrocketed 191.56% in 2023 before it decreased 25.03% in 2024.
  • Over 5 years, Operating Leases stood at $3.8 million in 2022, then rose by 16.68% to $4.4 million in 2023, then fell by 15.63% to $3.7 million in 2024, then fell by 20.45% to $3.0 million in 2025, then fell by 6.72% to $2.8 million in 2026.
  • Business Quant data shows Operating Leases for EWTX at $2.8 million in Q1 2026, $3.0 million in Q4 2025, and $3.2 million in Q3 2025.